$ADCT News

ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma

ADC Therapeutics (ADCT) Price Target Decreased by 61.40% to 1.87

ADC Therapeutics Announces Strategic Reorganization To Focus Resources Behind Key Value-Driving Initiatives In Support Of ZYNLONTA Franchise

HC Wainwright & Co. Downgrades ADC Therapeutics (ADCT)

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL - Slideshow

HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

ADC Therapeutics (ADCT) Price Target Decreased by% to 4.84

ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy

RBC Capital Downgrades ADC Therapeutics (ADCT)

RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript

ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript

ADC Therapeutics S.A. Q1 2026 Earnings Call Summary

ADCT Q1 2026 Earnings Call Transcript

Full Transcript: ADC Therapeutics Q1 2026 Earnings Call

ADC Therapeutics Q1 Earnings Call Highlights